Abstract

Optimizing the value of pharmaceutical spending is an important goal for effective and sustainable health systems. During the economic crisis, Greece undertook a set of strict fiscal policies to contain public pharmaceutical expenditure. The objective of this study is to investigate the social inefficiencies stemming from the regulatory framework of the Greek health system, with an emphasis on the effects of the policy reforms during the economic crisis on health outcomes.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call